Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

(2019) Luis Puig et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Immunogenicity and Skin Clearance Recapture in Clinical Studies of Brodalumab

(2019) Jerry Bagel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

(2019) Mark G. Lebwohl et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

(2018) C.E.M. Griffiths et al.   BRITISH JOURNAL OF DERMATOLOGY

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

(2018) Mark G. Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

Brodalumab: First Global Approval

(2016) Sarah L. Greig   DRUGS

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database

(2015) K. Kubota et al.   BMJ Open

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

(2014) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants

(2012) X.T. Lima et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY